Probiotic strain selection by condition: a practical guide

← Back to articles

The single most important principle in probiotic supplementation is that effects are strain-specific, not species-specific. Lactobacillus rhamnosus GG is not the same product as L. rhamnosus GR-1, and a generic "Lactobacillus" capsule is not interchangeable with a trial-validated strain at a trial-validated dose and formulation. Major guideline bodies and the International Scientific Association for Probiotics and Prebiotics (ISAPP) have repeatedly stressed this point, because clinical benefit demonstrated for one deposited strain does not automatically transfer to a relative on a supplement shelf. What follows is what the randomised-trial record actually supports, condition by condition — and, just as importantly, where it does not.

IBS: which strains have positive trials

Bifidobacterium longum 35624 (historically labelled Bifidobacterium infantis 35624) has the cleanest single-strain dose-finding evidence in IBS. In a large multicentre RCT of 362 women with IBS, the encapsulated strain at 1 × 10⁸ CFU/day beat placebo on abdominal pain and a composite symptom score over four weeks — while, strikingly, both a lower (1 × 10⁶) and a higher (1 × 10¹⁰) dose failed, a vivid demonstration that more is not better and that dose and formulation are part of the "strain" [1]. Lactobacillus plantarum 299v (DSM 9843) has its own supporting data: a double-blind trial in 214 Rome III IBS patients found that one capsule daily for four weeks reduced abdominal pain frequency and severity and bloating versus placebo [2]. Generic Lactobacillus acidophilus on its own does not have comparable IBS evidence and should not be treated as a substitute.

Antibiotic-associated diarrhoea

Two probiotics have repeatedly survived systematic review for preventing antibiotic-associated diarrhoea: the yeast Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG. Pooled trial data attribute roughly a halving of antibiotic-associated diarrhoea risk to adequately dosed S. boulardii, and because it is a yeast it is not itself killed by antibacterials — a practical advantage when given alongside a course [3]. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) working group makes a strong recommendation for either L. rhamnosus GG or S. boulardii to prevent antibiotic-associated diarrhoea in children when prevention is warranted, and suggests S. boulardii specifically when Clostridioides difficile-associated diarrhoea is the concern [4]. Timing matters: the benefit is greatest when the probiotic is started at, or within about 48 hours of, the first antibiotic dose.

Infant colic

Lactobacillus reuteri DSM 17938 is the best-studied strain for colic, but the headline finding is narrower than often claimed. An individual-participant-data meta-analysis of four double-blind RCTs (345 infants) found that the probiotic group cried and fussed about 25 minutes less per day at day 21 and was roughly twice as likely to reach "treatment success" — but the benefit was confined to breastfed infants (number needed to treat ≈ 3), with insufficient evidence to recommend it for formula-fed infants [5]. So the strain works, but the population matters: this is an evidence-based option for breastfed babies with colic, not a blanket fix, and other strains and blends do not carry equivalent data.

Inflammatory bowel disease

For ulcerative colitis, the multi-strain high-potency formulation originally sold as VSL#3 (and now as Visbiome) — eight strains across Lactobacillus, Bifidobacterium, and Streptococcus — has the most trial support among probiotics, with evidence in mild-to-moderate disease and, most consistently, in pouchitis, where it is used to maintain remission after antibiotic induction [6]. Escherichia coli Nissle 1917 has European data suggesting non-inferiority to mesalamine for maintaining remission in ulcerative colitis. Crucially, no single-strain Lactobacillus product has IBD evidence approaching this, and probiotics are an adjunct to — not a replacement for — standard IBD therapy.

Vaginal and urinary-tract health

Lactobacillus rhamnosus GR-1 plus L. reuteri RC-14, taken orally, has randomised evidence for improving vaginal flora. In a placebo-controlled trial in postmenopausal women with intermediate Nugent scores, two weeks of the oral combination shifted significantly more women toward a normal vaginal flora than placebo (60% vs 16%) [7]. The effect sizes across this indication are modest and the literature is smaller than the "women's health" marketing implies; other Lactobacillus blends sold for vaginal or urinary health generally lack strain-specific trial support.

Common errors in interpretation

First, dose is part of the prescription: the B. longum 35624 trial showed a strain working at 10⁸ CFU yet failing at both 10⁶ and 10¹⁰, so a product with the right organism at the wrong dose is not "the same thing" [1]. Second, multi-strain is not automatically better — combination products should be tested as the specific combination, because evidence for individual components does not transfer to a blend. Third, storage and shelf-life matter: many probiotics lose viability at room temperature, and a label CFU count usually reflects the count at manufacture, not what survives to the expiry date. The throughline is simple: match a named, trial-validated strain to the indication, at the dose and formulation actually studied, or accept that you are extrapolating beyond the evidence.

Sources

1. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EMM. "Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome." Am J Gastroenterol, 2006;101(7):1581-1590. PMID 16863564. DOI: 10.1111/j.1572-0241.2006.00734.x.
2. Ducrotté P, Sawant P, Jayanthi V. "Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome." World J Gastroenterol, 2012;18(30):4012-4018. PMID 22912552. DOI: 10.3748/wjg.v18.i30.4012.
3. Waitzberg D, Guarner F, Hojsak I, Ianiro G, Polk DB, Sokol H. "Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?" Adv Ther, 2024;41(3):901-914. PMID 38286962. DOI: 10.1007/s12325-024-02783-3.
4. Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, et al. "Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children." J Pediatr Gastroenterol Nutr, 2016;62(3):495-506. PMID 26756877. DOI: 10.1097/MPG.0000000000001081.
5. Sung V, D'Amico F, Cabana MD, Chau K, Koren G, Savino F, et al. "Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis." Pediatrics, 2018;141(1):e20171811. PMID 29279326. DOI: 10.1542/peds.2017-1811.
6. Gionchetti P, Calafiore A, Praticò C, Laureti S, Vitali G, Poggioli G, Campieri M, Rizzello F. "Randomized controlled trials in pouchitis." Rev Recent Clin Trials, 2012;7(4):303-306. PMID 23092236. DOI: 10.2174/1574887111207040303.
7. Petricevic L, Unger FM, Viernstein H, Kiss H. "Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women." Eur J Obstet Gynecol Reprod Biol, 2008;141(1):54-57. PMID 18701205. DOI: 10.1016/j.ejogrb.2008.06.003.